REG - AstraZeneca PLC - Annual Financial Report <Origin Href="QuoteRef">AZN.L</Origin> - Part 30
- Part 30: For the preceding part double click ID:nRSH4027RC
control could result in the failure of the supply of goods and services.
For example, suppliers of key goods may cease to trade or experience
supply chain failures such as those described under the risk above. In
addition, we may experience limited supply of biological materials, such
as cells, animal products or by-products. Furthermore, government
regulations could result in restricted access to, use or transport of
such materials. Manufacturing biologicsManufacturing biologics,
especially in large quantities, is complex and may require the use of
innovative technologies to handle living micro-organisms and facilities
specifically designed and validated for this purpose, with sophisticated
quality assurance and control procedures.Final market release of a
biologic depends on a number of in-process manufacturing and supply chain
- More to follow, for following part double click ID:nRSH4027RERecent news on AstraZeneca
See all newsREG - AstraZeneca PLC - Tozorakimab met OBERON/TITANIA primary endpoints
AnnouncementREG - AstraZeneca PLC - Notification of Admission of Shares
AnnouncementREG - AstraZeneca PLC - Imfinzi approved in EU for early gastric cancer
AnnouncementREG - AstraZeneca PLC - Notice of AGM
AnnouncementRCS - Redx Pharma Limited - RXC008 Receives US FDA Fast Track Designation
Announcement